The 2024 iteration of the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Breast Cancer provides a critical framework for the evidence-based, multidisciplinary management of nonmetastatic disease. This review synthesizes the updated recommendations for systemic therapy, including cytotoxic, endocrine, and targeted biologic agents. Emphasis is placed on tailoring therapeutic regimens to specific molecular subtypes and individual patient risk profiles. Adherence to these guidelines is paramount for optimizing oncologic outcomes, minimizing treatment-related toxicity, and standardizing high-quality clinical practice across diverse care settings.